KFAED, Bahrain sign $32.4mln loan deal for Sheikh Jaber Al-Ahmad Highway
MANAMA - The Kuwait Fund for Arab Economic Development (KFAED) and Bahrain's government signed on Sunday a loan agreement estimated at KD 10 million (about USD 32.4 million) to fund the second phase of developing the project of Sheikh Jaber Al-Ahmad Al-Sabah Highway.
The project aims to back Bahrain's social and economic development through evolving one of the main vital highways in the capital.
It is expected to partake in achieving some sustainable development goals, including infrastructure, and enhancing local cities and communities' sustainability as well as reducing carbon emissions caused by traffic.
The scheme also includes expanding Sheikh Jaber Al-Ahmad Al-Sabah Highway from three to four lanes in each direction along 11 km, in addition to setting up five bridges.
The scheme's total cost is evaluated at USD 404.4 billion, and the KFAED covers about 8 percent of this cost.
Under the deal, the loan agreement, with a term of 20 years and a grace period of eight years, will be repaid in 24 semi-annual instalments.
The loan carries an interest rate of three percent per annum, with an additional 0.5 percent per annum fee to cover administrative costs and services related to the loan agreement. It is the 22nd loan offered by the fund to Bahrain.
The deal was signed by Acting Director General of KFAED Waleed Al-Bahar and Bahrain's Minister of Finance and National Economy Sheikh Salman bin Khalifa, in the presence of Kuwait's Ambassador to Bahrain Sheikh Thamer Jaber Al-Ahmad Al-Sabah.
All KUNA right are reserved © 2022. Provided by SyndiGate Media Inc. (Syndigate.info).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
14 hours ago
- Arabian Post
Loyyal Expands Maharaja Club with Global Shopping Rewards
Air India has partnered with blockchain-based loyalty specialist Loyyal to allow Maharaja Club members to earn points on everyday purchases across key brands in the United States and the United Kingdom. The collaboration enables members to accrue Maharaja Points on shopping at major retailers such as Walmart, Victoria's Secret, New Balance, GAP, Victorinox and Alamo – marking a significant expansion of the airline's loyalty programme. Members now earn up to 99 Maharaja Points per USD 100 spent at Walmart, 310 points per GBP 100 at Victoria's Secret, 300 points at Victorinox, 45 at New Balance, 180 at GAP and 64 points at Alamo. These offerings are accessible via the Maharaja Club Partner Offers page on Air India's website, where members can select a brand and follow on-screen prompts to initiate their purchases. Shailesh Kumar Singh, Head of Loyalty at Air India, commented that the alliance with Loyyal 'makes it easier for our members to earn Maharaja Points on everyday essentials and shopping, without needing to fly frequently'. Meanwhile, Loyyal CEO Ashish Kumar Singh noted that the initiative 'significantly boosts the earning potential for Maharaja Club's members,' adding that it enriches daily experiences and complements travel benefits. ADVERTISEMENT The partnership follows a broader revamp of the Maharaja Club, which adopted a simplified tier structure, updated identity and enhanced customer features. Air India has added more than 50 non-airline partners over the last 18 months, supporting its transformation under the strategy and leveraging its Star Alliance membership. The move aligns with global loyalty trends, where airlines increasingly engage shoppers via retail partnerships. By enabling points accrual through non-travel spend, loyalty programmes become more relevant to everyday consumer behaviour, fostering engagement beyond flight activity. Consumers, meanwhile, gain tangible value even during non-travel periods. Maharaja Club's integration with Star Alliance further enhances its value proposition. As noted by Air India's own commentary, elite-tier members benefit from worldwide priority check-in, lounge access at over 1,100 locations, extra baggage allowance, and the ability to accrue and redeem points across the alliance's 25 carriers. These features remain central to the programme's repositioning. Industry analysts highlight that Loyyal's blockchain-based platform offers secure, transparent point tracking and easier integration of diverse partners. Though Air India and Loyyal have not disclosed technical details publicly, Loyyal's existing reputation in travel loyalty schemes supports confidence in seamless implementation. Under the agreement, Air India continues to broaden access to Maharaja Points across shopping categories. The move targets customers traveling abroad or residing outside India, reinforcing Air India's global outreach following its Tata Group-led transformation. In support, the programme emphasises that points can be redeemed for award flights and cabin upgrades through Air India or Star Alliance partners. The timing of the launch coincides with Air India's widened network with new interline agreements and route expansions, such as recent pacts with airlines like airBaltic, Cyprus Airways and Uzbekistan Airways, aimed at increasing global connectivity. As passengers gain more travel options, the value of earning and using loyalty points is projected to grow. As more household and lifestyle brands are added to the programme, members could diversify their point accrual even further. Air India has indicated that additional partners will be announced in due course, though specifics have not yet been released. Maharaja Club members benefit from streamlined user experience with clearly stated earning rates for each participating brand. For example, spending at Victoria's Secret yields 310 points per GBP 100, while spending at Victorinox delivers 300 points per USD 100 – figures that are prominently showcased on the shopping portal. Air India's alignment with Loyyal fits within its hospitality-driven repositioning under along with fleet modernisation, training investments, new routes, and enhanced premium services. The airline aims to appeal to international leisure and business travellers – particularly those based abroad – by offering points that can accrue through both travel and lifestyle spending. Industry commentators suggest that Loyyal's blockchain solution offers underlying benefits including transparent audit trails, fraud reduction and easy tracking of reward accrual from non-travel sources. This increases both partner and consumer confidence in the integrity of the loyalty ecosystem.
Arabian Post
15 hours ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
Arabian Post
15 hours ago
- Arabian Post
UK Fintech OpenTrade Secures £5.5M to Boost Stablecoin Yield Services
OpenTrade, a London-based fintech infrastructure provider, has closed a £5.5 million funding round, led by Notion Capital and Mercury Fund, raising its total capital to around £8.5 million since inception. The investment is earmarked to scale its build-out of real-world asset-backed stablecoin yield services across high-inflation markets in Latin America and Europe. OpenTrade embeds 'yield-as-a-service' into fintech apps, allowing users to earn interest on USD and EUR stablecoins—rates that significantly outperform traditional banking options. Fintech clients such as Criptan in Spain and Littio in Colombia now offer yields up to 9%, compared with local bank APRs of under 0.5%. Co-founders Dave Sutter, Jeff Handler, and Tom Niermann have close links to USDC's Centre consortium and hold decades of digital assets experience. They launched OpenTrade in early 2024 to address demand from emerging markets, where inflation erodes savings and dollar-denominated banking returns are negligible. The platform has since managed approximately $47 million in assets and processed nearly $200 million in transaction volume, growing at an average of 20% month-over-month. ADVERTISEMENT The round also saw participation from a16z crypto, AlbionVC, and CMCC Global, reflecting continued investor confidence. OpenTrade intends to direct the funds towards enhancing its technological capabilities, supporting growth in client-facing applications, and broadening its product suite to include a wider range of real-world asset-backed instruments. The company's timing aligns with a broader surge in stablecoin infrastructure. Globally, stablecoin transaction volumes now exceed $20 trillion annually—outpacing conventional payment systems such as Visa, Mastercard, and PayPal. For fintech firms in emerging economies, embedding stablecoin yields into everyday platforms is reshaping perceptions of crypto, transforming digital currencies from purely transactional tools into accessible savings vehicles. Argentina and Colombia exemplify this shift. Dollar accounts are rare, and where available, yields are negligible. In Colombia, dollar-denominated APRs are below 0.4%, while Littio users, through OpenTrade, attract up to 6%. Spain's Criptan offers up to 9% in EUR stablecoin returns—generating user traction by outperforming traditional savings products. Despite the rapid uptake of stablecoins, mainstream users in many regions face roadblocks: regulatory frameworks for safe yield generation have lagged behind adoption. OpenTrade bridges this gap by offering compliant real-world asset backing and embedded yield capabilities, supporting regulatory alignment while extending market reach. This funding arrives amid a regulatory pivot in Europe. The Financial Conduct Authority plans to unveil discussion papers on stablecoin issuance and custody in Q4 2025, aligning with the EU's Markets in Crypto-Assets framework. OpenTrade's growth strategy demonstrates fintechs' ambition to navigate both innovation and regulation in stablecoin infrastructure. Fintech founders view embedded stablecoin yield as essential for financial inclusion. Sutter has emphasized that stablecoins have become crypto's 'killer app' and that over a third of Latin American consumers have used them for purchases. OpenTrade is positioned as an enabler: the platform supports deposits, withdrawals, and yield generation directly within existing fintech interfaces. Investor sentiment adds context. Notion Capital's Itxaso del Palacio remarked that the $240 billion stablecoin market needs robust infrastructure. Mercury Fund's Samantha Lewis described OpenTrade as 'core financial infrastructure for the next generation of fintech'. These endorsements highlight confidence in both OpenTrade's leadership and market relevance. Looking ahead, OpenTrade aims to expand its reach over the next 12–18 months. Key areas include launching new yield products, incorporating diverse asset classes, and enhancing the user experience for fintech clients. The vision is to become the go-to partner for compliant stablecoin yield solutions, competing across developed and emerging economies where rising inflation, currency volatility, and limited access to traditional deposits persist.
